Wide Ranks

ALRN

Aileron Therapeutics, Inc.

2.74

Top Statistics
Market Cap 59 M Forward PE -1.46 Revenue Growth 0.00 %
Current Ratio 4.69 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.36 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 21 M Total Cash Per Share 1.01 Total Debt
Total Debt To Equity Current Ratio 4.69 Book Value Per Share 1.41
All Measures
Short Ratio 347.00 % Message Board Id finmb_21766697 Shares Short Prior Month 297745
Return On Equity -0.4432 City Austin Uuid aab0072b-67d5-3152-ae06-7c7794bcf03f
Previous Close 2.56 First Trade Date Epoch Utc 1 B Book Value 1.41
Beta 2.34 Volume 67638 Price To Book 1.94
Last Split Date 1 B Fifty Two Week Low 1.61 Total Cash Per Share 1.01
Shares Short Previous Month Date 1 B Target Median Price 13.00 Max Age 86400
Recommendation Mean 1.00 Sand P52 Week Change 0.3133 Target Mean Price 13.00
Net Income To Common -25221000 Short Percent Of Float 0.0108 Implied Shares Outstanding 21 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 84800
Average Volume10days 84800 Total Cash 21 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0065 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.56 Target Low Price 7.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.46 Open 2.61
Free Cashflow -12065875 State TX Dividend Yield 0.00 %
Return On Assets -0.2586 Time Zone Short Name EST Trailing Eps -2.88
Day Low 2.55 Address1 12407 N. Mopac Expy. Shares Outstanding 21 M
Price Hint 4 Target High Price 19.00 Website https://www.aileronrx.com
52 Week Change 0.2925 Average Volume 80748 Forward Eps -1.78
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 443.90 %
Last Split Factor 1:20 Regular Market Day High 2.83 Is_sp_500 False
Profit Margins 0.00 % Fifty Two Week High 7.42 Day High 2.83
Shares Short 233272 Regular Market Open 2.61 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0108
Operating Cashflow -25691000 Currency USD Time Zone Full Name America/New_York
Market Cap 59 M Is_nasdaq_100 False Zip 78758
Quote Type EQUITY Industry Biotechnology Long Name Aileron Therapeutics, Inc.
Regular Market Day Low 2.55 Held Percent Institutions 0.2847 Current Price 2.74
Address2 Suite 250 #390 Enterprise To Ebitda -3.36 Financial Currency USD
Current Ratio 4.69 Industry Disp Biotechnology Number Of Analyst Opinions 2
Country United States Float Shares 19 M Two Hundred Day Average 3.70
Enterprise Value 85 M Forward PE -1.46 Regular Market Volume 67638
Ebitda -25396000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.

The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.

The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications.

The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007.

Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.